Cargando…
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse r...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891690/ https://www.ncbi.nlm.nih.gov/pubmed/28304217 http://dx.doi.org/10.1177/1352458517695468 |
_version_ | 1783313043441057792 |
---|---|
author | Freedman, Mark S Wolinsky, Jerry S Comi, Giancarlo Kappos, Ludwig Olsson, Tomas P Miller, Aaron E Thangavelu, Karthinathan Benamor, Myriam Truffinet, Philippe O’Connor, Paul W |
author_facet | Freedman, Mark S Wolinsky, Jerry S Comi, Giancarlo Kappos, Ludwig Olsson, Tomas P Miller, Aaron E Thangavelu, Karthinathan Benamor, Myriam Truffinet, Philippe O’Connor, Paul W |
author_sort | Freedman, Mark S |
collection | PubMed |
description | Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies. |
format | Online Article Text |
id | pubmed-5891690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-58916902018-04-13 The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies Freedman, Mark S Wolinsky, Jerry S Comi, Giancarlo Kappos, Ludwig Olsson, Tomas P Miller, Aaron E Thangavelu, Karthinathan Benamor, Myriam Truffinet, Philippe O’Connor, Paul W Mult Scler Short Reports Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies. SAGE Publications 2017-03-17 2018-04 /pmc/articles/PMC5891690/ /pubmed/28304217 http://dx.doi.org/10.1177/1352458517695468 Text en © The Author(s), 2017 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Short Reports Freedman, Mark S Wolinsky, Jerry S Comi, Giancarlo Kappos, Ludwig Olsson, Tomas P Miller, Aaron E Thangavelu, Karthinathan Benamor, Myriam Truffinet, Philippe O’Connor, Paul W The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies |
title | The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies |
title_full | The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies |
title_fullStr | The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies |
title_full_unstemmed | The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies |
title_short | The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies |
title_sort | efficacy of teriflunomide in patients who received prior disease-modifying treatments: subgroup analyses of the teriflunomide phase 3 temso and tower studies |
topic | Short Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891690/ https://www.ncbi.nlm.nih.gov/pubmed/28304217 http://dx.doi.org/10.1177/1352458517695468 |
work_keys_str_mv | AT freedmanmarks theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT wolinskyjerrys theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT comigiancarlo theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT kapposludwig theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT olssontomasp theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT milleraarone theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT thangavelukarthinathan theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT benamormyriam theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT truffinetphilippe theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT oconnorpaulw theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT theefficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT freedmanmarks efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT wolinskyjerrys efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT comigiancarlo efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT kapposludwig efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT olssontomasp efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT milleraarone efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT thangavelukarthinathan efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT benamormyriam efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT truffinetphilippe efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT oconnorpaulw efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies AT efficacyofteriflunomideinpatientswhoreceivedpriordiseasemodifyingtreatmentssubgroupanalysesoftheteriflunomidephase3temsoandtowerstudies |